Leading Pharmaceutical manufacturer, Allergan Inc. of the USA continues to seek to expand the use of its wrinkle smoother Botox into other medical uses with an eye on the Incontinence Market. Allergan say that injections of the drug into the bladder helped decrease symptoms of severe urinary incontinence in two studies.

Botox led to a “statistically significant” decline in incontinence among patients with overactive bladder, the Irvine, California-based company said in a statement today. Based on the results, Allergan said it has applied for approvals from the U.S. Food and Drug Administration and European Union officials.

Botox, Allergan’s best-selling product, had $1.59 billion in sales last year, about half for cosmetic uses and half for migraine treatment, incontinence and other conditions.

The company was able to enroll patients in the trials and collect data faster than expected, the CEO said. A regulatory decision from the FDA should come by early next year, he said. The studies treated patients with overactive bladders not caused by a neurological condition and who had failed to respond to standard medication, according to the company’s statement.